Biotroy Therapeutics

Location not on file

OncologyvaccinePhase I

What changed

Phase I trial registered: A Clinical Study of BT02 for the Treatment of Patients With Advanced Malignant Melanoma

11mo agoTrial registeredAug 6, 2025Source filing (opens the source filing in a new tab)

Momentum

46no change

Some recent activity, at a steady rate.

Runway (estimate)

—unknown

No disclosed raise on file, so there is nothing to model from.

Stage

Phase I

The furthest-along thing in the public record. Not a projection.

Runway is an estimate: the last disclosed raise (SEC Form D) minus a modeled burn rate for the company’s stage and therapeutic area. It is not a disclosure, and companies routinely raise non-dilutive money we can’t see. How this is calculated.

Grant to raise

Every record Biodatica has resolved onto this company, newest first, each linked to the filing it came from. Where a source publishes no stable deep link for a record, the identifier is shown so you can look it up yourself.

Trial
PHASE1 registered
Aug 8, 2025
Advanced Melanoma, Advanced Solid Tumor · NOT_YET_RECRUITING · sponsor: Biotroy Therapeutics · A Clinical Study of BT02 for the Treatment of Patients With Advanced Malignant Melanoma
ClinicalTrials.gov · NCT07107178 (opens the source filing in a new tab)
Grant
R01 · $723k · non-dilutive
Aug 15, 2024
UNIVERSITY OF FLORIDA · PI GUO, JINGCHUAN · NIA · award ends Apr 30, 2029 · iSMART: intelligent Social risk Management in AD/ADRD paTients
NIH RePORTER · NIH RePORTER 11169926 (opens the source filing in a new tab)
Grant
R35 · $370k · non-dilutive
Jul 15, 2023
UNIVERSITY OF NEBRASKA LINCOLN · PI GUO, JIANTAO · NIGMS · award ends Jun 30, 2028 · Developing synthetic chemical biology strategies for biochemical investigations and biomedical applications
NIH RePORTER · NIH RePORTER 11133040 (opens the source filing in a new tab)

How this crosswalk was built

Confidence 100%Edges merged automatically, not yet reviewed by a human

Shared principal investigator or founder links the grant record at 0.75{"reasons":["principal investigator GUO, JINGCHUAN is named on this company's filings"]}
Shared principal investigator or founder links the grant record at 0.75{"reasons":["grant to an academic institution linked by a shared principal investigator"]}
new_entity links the trial record at 0.42{"reasons":["no candidate cleared the review threshold"]}

Links score at or above 0.86 to merge automatically. Anything below that and above the review line goes to a human queue. Resolution is a judgment, and it can be wrong. How resolution works.

Event stream

Every scored event, newest first. This is what momentum is computed from.

Phase I trial registered: A Clinical Study of BT02 for the Treatment of Patients With Advanced Malignant Melanoma
11mo agoTrial registeredSource (opens the source filing in a new tab)
NIH R35 · $0.4M · Developing synthetic chemical biology strategies for biochemical investigations and biomedical applications
Jun 2025Grant renewalSource (opens the source filing in a new tab)
NIH R01 · $0.7M · iSMART: intelligent Social risk Management in AD/ADRD paTients
Apr 2025Grant renewalSource (opens the source filing in a new tab)

Last disclosed raise

No Form D is on file, so there is no raise to model a runway from. That is why the runway reads “—” rather than a number. It does not mean the company has no money: grants, revenue and notes below the Form D threshold are all invisible here.

Something wrong on this page? The crosswalk is a judgment and we would rather hear it. Report a bad link.

Biodatica publishes impersonal research shown identically to every subscriber. This dossier is informational only, it is not investment advice, and the momentum and runway figures are estimates derived from public filings. The underlying records are U.S. government works. Disclosures · Data sources

Grant to raise

PHASE1 registered

R01 · $723k · non-dilutive

R35 · $370k · non-dilutive